Maastricht Univerisity Medical Center Commences Procedures
24.2.2021 23:47:00 EET | Business Wire | Press release
Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce the Maastricht University Medical Centre+ (MUMC+) in the Netherlands has commenced procedures since the extended lockdowns across Europe precluded elective surgeries. The team at MUMC+ successfully performed two atrial flutter ablations yesterday.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224006030/en/
Dr. Marisevi Chaldoupi performing an atrial flutter ablation with Imricor's products at MUMC+ in a standard MRI suite equipped to function as an iCMR lab (Photo: Business Wire)
Electrophysiologist, Dr. Marisevi Chaldoupi, MD PhD, commented: “Today in our ablation we realized that we were limited in the past, and now we can see what we are doing. While we have just started in iCMR, it is obvious to see the future of this technology and where it will take us and patient treatment.”
Imricor’s Chair and CEO, Steve Wedan, commented: “This is great news and an exciting step forward, as we start to put COVID behind us. We continue to actively plan for the easing of COVID restrictions, including scheduling training and installation at new sites and supporting the recommencement of procedures at existing sites. We also expect to begin signing new labs again soon, growing our installed base.
“Notably, MUMC+ is one of the sites where cardiology and radiology are partnering to utilize an existing MRI suite as an iCMR lab as a way to start performing ablations using Imricor’s products immediately, while future plans are being made for constructing dedicated iCMR lab facilities. They are a model for other sites who want to get started in a similar way.”
Dr Miranda Bijvoet, MD (imaging Cardiologist) and Dr Casper Mihl, MD (Radiologist) together stated: “Today proved that it is feasible to turn a diagnostic MR into an iCMR lab, and the technique has great potential as we were able to evaluate the ablation lesion and validate the treatment in the right position. This is a great collaboration between cardiology and radiology.”
Rob Holtackers, PhD (MR Physicist) added: “Combining the best imaging with the best of electrophysiology practice allows us to provide better patient care. The partnership is making this amazing project work.”
About Imricor
Please visit http://imricor.com/investors/about-imricor/ for more information about Imricor, Foreign Ownership Restrictions, and Forward-Looking Statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224006030/en/
Contact information
Investors:
Steve Wedan
Executive Chair, President and CEO
Email: steve.wedan@imricor.com
Investors & Australian Media:
Carrie Barrack
Senior Advisor, Cato & Clive
Email: carrie@catoandclive.com
Mobile: +61 422 464 028
Rest of World Media:
Nick Twohy
Director of Marketing, Imricor
Email: nick.twohy@imricor.com
Phone: +1 952 818 8407
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AIT Worldwide Logistics Welcomes Justin Kosslyn as Chief Digital and Technology Officer13.7.2026 18:02:00 EEST | Press release
Supply chain solutions leader AIT Worldwide Logistics has hired Justin Kosslyn, a tenured software development executive, as its chief digital and technology officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713269550/en/ Justin Kosslyn will lead an accelerating digital transformation at AIT Worldwide Logistics, unifying a vastly diverse array of shippers and partners across the globe. In the newly created role, Kosslyn will report directly to President and Chief Operating Officer, Keith Tholan, and lead the company’s global technology strategy, continuing to implement AIT’s existing program while accelerating the next generation of integrated digital, data, AI and customer-facing systems across the organization. “With a history of delivering for companies at the center of global technology and innovation, Justin brings the kind of forward-looking perspective we believe can help AIT lead the next evolution of logist
Labaton Keller Sucharow LLP Launches Corporate Accountability & Governance Task Force13.7.2026 17:46:00 EEST | Press release
Labaton Keller Sucharow LLP is pleased to announce the launch of its new Corporate Accountability & Governance Task Force, designed to help institutional investors advance corporate accountability while pursuing meaningful shareholder recoveries. Created in response to the increasing needs of our clients, the Task Force will provide clients with strategic advice on opportunities to drive positive corporate change through securities and shareholder litigation. This initiative reflects the Firm’s longstanding commitment to protecting investor interests while promoting responsible corporate conduct. Labaton partners with institutional investor clients to pursue cases that not only seek financial recovery but also encourage meaningful corporate reforms and reinforce sound governance practices. The Task Force is chaired by Partners Carol C. Villegas and Domenico “Nico” Minerva, who have led some of the Firm's most significant matters involving corporate accountability and governance reform.
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 16:30:00 EEST | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and execution management workflow is becoming increasingly important. FlexTrade's integration with Portx builds on FlexONE's existing real-time front-office risk analytics capabilities, inclu
Xsolla Connect Returns to Brighton13.7.2026 16:22:00 EEST | Press release
Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event will build on that momentum by providing attendees with a dedicated space to connect with peers
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom